Two phase III studies, PROFILE 1007 [9] and PROFILE 1014 [10], provided further proof in favor of the use of crizotinib over standard second-line chemotherapy and over first-line chemotherapy, respectively in advanced ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.